In addition, because the demonstration will operate outside the Part D benefit, the manufacturers wont be responsible for providing the manufacturer price discount on eligible GLP-1s (10% in the Part D initial benefit phase and 20% in the catastrophic phase.) While many prior section 402 demonstrations have had to conform to budget neutrality rules by the Office of Management and Budget (OMB), some demonstrations have been able to move forward without this requirement
[DOI] [PubMed] [Google Scholar] 106.Fisman E.Z., Tenenbaum A
This makes GLP-1 agonists valuable therapeutic options for managing type 2 diabetes, especially when lifestyle modifications and other oral medications are not sufficient
10.1177/0271678X16629153 119
Peptide therapy should only be undertaken under the guidance of a qualified healthcare provider
And Dr Aiken is right that there's no reason to neglect methylfolate in the context of some autisms, particularly where 'issues' with a certain gene - MTHFR - may also be present